Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.

摘要: Immune checkpoint inhibitors (ICI) are an important development in the treatment of advanced cancer. A substantial proportion patients treated with ICI do not respond, and additionally discontinue due to adverse effects. While many novel biological markers related specific mechanisms actions have been investigated, there has also considerable research identify routinely available blood clinical that may predict response therapy. If validated, these advantage being easily integrated into use for nominal expense. Several shown promise, including baseline post-treatment changes leucocyte counts, lactate dehydrogenase C-reactive protein. promising, results between studies inconsistent small sample sizes, follow-up time variability assessed markers. To date, on focussed primarily melanoma, ipilimumab univariate associations, but preliminary evidence is emerging other cancer types, ICIs combining multivariable prediction models.